Analysts’ Weekly Ratings Changes for Chemours (CC)

A number of firms have modified their ratings and price targets on shares of Chemours (NYSE: CC) recently:

• 11/4/2026 – Chemours had its price target lowered by UBS Group from $16.00 to $15.00. They now have a “neutral” rating on the stock.
• 11/4/2026 – Chemours had its price target lowered by Truist Financial from $20.00 to $18.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Chemours had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/20/2026 – Chemours had its price target lowered by Truist Financial from $24.00 to $20.00. They now have a “buy” rating on the stock.
• 10/14/2026 – Chemours was downgraded by Mizuho from “outperform” to “neutral”. They now have a $15.00 price target on the stock, down from $18.00.
• 10/13/2026 – Chemours was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $14.00 price target on the stock.
• 10/13/2026 – Chemours was downgraded by Mizuho from “strong-buy” to “hold”.
• 10/12/2026 – Chemours is now covered by Barclays. They set an “equal weight” rating and a $16.00 price target on the stock.
• 10/12/2026 – Chemours was upgraded by Barclays to “hold”.
• 10/9/2026 – Chemours had its “neutral” rating reaffirmed by The Goldman Sachs Group. They now have a $16.00 price target on the stock.
• 10/5/2026 – Chemours had its price target lowered by UBS Group from $18.00 to $16.00. They now have a “neutral” rating on the stock.
• 9/30/2026 – Chemours had its price target lowered by Mizuho from $20.00 to $18.00. They now have an “outperform” rating on the stock.
• 9/10/2026 – Chemours was upgraded by Zacks Research from “strong sell” to “hold”.

Chemours Trading Up 5.1%

NYSE CC opened at $13.76 on Thursday. The company has a market cap of $2.07 billion, a price-to-earnings ratio of -13.49 and a beta of 1.47. The business has a 50 day moving average price of $14.08 and a 200-day moving average price of $18.25. The company has a quick ratio of 0.88, a current ratio of 1.81 and a debt-to-equity ratio of 24.25. The Chemours Company has a 52 week low of $10.44 and a 52 week high of $28.67.

Chemours (NYSE:CC) last released its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.05). Chemours had a positive return on equity of 76.52% and a negative net margin of 2.64%. The business had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.53 billion. During the same quarter in the previous year, the company posted $0.40 EPS. The business’s quarterly revenue was up 3.0% on a year-over-year basis. As a group, equities analysts expect that The Chemours Company will post 0.83 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be given a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, November 16th. Chemours’s dividend payout ratio is presently -34.31%.

Insider Activity

In other Chemours news, insider Calderon Gerardo Familiar purchased 1,935 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the acquisition, the insider owned 58,547 shares of the company’s stock, valued at $909,234.91. The trade was a 3.42% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Denise Dignam purchased 3,378 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was bought at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the completion of the acquisition, the chief executive officer directly owned 339,916 shares in the company, valued at $5,081,744.20. The trade was a 1.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.85% of the company’s stock.

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.